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Abstract
Cerebral cavernous malformations (CCMs) are vascular malforma-
tions located within the central nervous system often resulting in
cerebral hemorrhage. Pharmacological treatment is needed, since
current therapy is limited to neurosurgery. Familial CCM is caused
by loss-of-function mutations in any of Ccm1, Ccm2, and Ccm3
genes. CCM cavernomas are lined by endothelial cells (ECs) under-
going endothelial-to-mesenchymal transition (EndMT). This switch
in phenotype is due to the activation of the transforming growth
factor beta/bone morphogenetic protein (TGFb/BMP) signaling.
However, the mechanism linking Ccm gene inactivation and TGFb/
BMP-dependent EndMT remains undefined. Here, we report that
Ccm1 ablation leads to the activation of a MEKK3-MEK5-ERK5-
MEF2 signaling axis that induces a strong increase in Kruppel-like
factor 4 (KLF4) in ECs in vivo. KLF4 transcriptional activity is
responsible for the EndMT occurring in CCM1-null ECs. KLF4
promotes TGFb/BMP signaling through the production of BMP6.
Importantly, in endothelial-specific Ccm1 and Klf4 double knockout
mice, we observe a strong reduction in the development of CCM
and mouse mortality. Our data unveil KLF4 as a therapeutic target
for CCM.
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Introduction
Cerebral cavernous malformation (CCM) is a vascular dysplasia
with a prevalence of 0.5% of the human population that affects
almost exclusively the venous microvasculature of the central
nervous system and of the retina (Labauge et al, 2007; Riant et al,
2010). Cavernomas are formed by mulberry-like enlarged and irreg-
ular blood vessels that often lack the support of mural cells and
tend to bleed (Tomlinson et al, 1994; Maraire & Awad, 1995;
Clatterbuck et al, 2001) causing several neurological symptoms
including headache, seizure, paralysis, and hemorrhagic stroke
(Cavalcanti et al, 2012). Location and number of lesions determine
the severity of this disorder (Moriarity et al, 1999). To date, the
only therapy available is neurosurgery (Rigamonti et al, 1988; Li &
Whitehead, 2010) that, however, is frequently hazardous. CCM
occurs as sporadic (80% of the cases) or familial (20% of the cases)
form with high penetrance. Familial CCM is an autosomic dominant
genetic disorder caused by loss-of-function mutations in anyone of
three genes, namely Ccm1 (Krit1), Ccm2 (Osm), and Ccm3 (Pdcd10)
(Laberge-le Couteulx et al, 1999; Bergametti et al, 2005; Labauge
et al, 2007; Riant et al, 2013).
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Similarly to patients, in murine models the vascular pheno-
type can be faithfully reproduced by endothelium-specific loss-of-
function mutations of anyone of these three Ccm genes (Liebner
et al, 2008; Boulday et al, 2011; Chan et al, 2011; McDonald
et al, 2011; Maddaluno et al, 2013; Mleynek et al, 2014). CCM
tripartite cytoplasmic complex controls barrier functions both by
inhibiting the small GTPase RhoA (Whitehead et al, 2009; Bori-
kova et al, 2010; Stockton et al, 2010) and by acting as an
effector of the small GTPase Ras-related protein 1 (Rap1) at the
cell-to-cell adherens junctions (AJ) in the endothelium (Beraud-
Dufour et al, 2007; Glading et al, 2007; Glading & Ginsberg,
2010; Fisher & Boggon, 2013). Recently, we extended these obser-
vations showing, both in vitro and in vivo, that in the absence of
CCM endothelial AJ are dismantled (Lampugnani et al, 2010; Boul-
day et al, 2011; Maddaluno et al, 2013) and endothelial cells (ECs)
lining the cavernomas undergo endothelial-to-mesenchymal transi-
tion (EndMT) (Maddaluno et al, 2013) induced by a strong activa-
tion of the phospho-SMAD-dependent signaling pathway due to an
increased endogenous production of the BMP6 ligand. During
EndMT, CCM-null ECs reduce the expression of specific endothelial
markers (such as Vascular-Endothelial (VE)-CADHERIN and
CLAUDIN5), acquire typical mesenchymal and stemness-associated
factors (including Inhibitor of Differentiation 1 ID1, Fibroblast-
Specific Protein 1 FSP1, Stem Cell Antigen1 SCA1, and Kruppel-like
factor 4 KLF4), and show increase in proliferation and migration
(James et al, 2010; Liang et al, 2011; Medici & Kalluri, 2012). TGFb/
BMP-driven EndMT as well as MAPK-dependent EndMT is impli-
cated in several pathological conditions (Zeisberg et al, 2007; Kitao
et al, 2009; Medici et al, 2010; Chen et al, 2012; Garcia et al, 2012),
and key molecules controlling this biological process are under
investigation.
KLF4, a zinc finger transcription factor of the Kruppel-like
factor family (KLF) (Garrett-Sinha et al, 1996; Shields et al, 1996),
is strongly upregulated in both the lesions and the pseudo-normal
vasculature of endothelial-specific CCM1 KO mice (Maddaluno
et al, 2013). KLF4 regulates different vascular functions such as
angiogenesis (Ohnesorge et al, 2010; Hale et al, 2014), vascular
tone and permeability (Cowan et al, 2010; Shatat et al, 2014),
coagulation and inflammatory reactions (Hamik et al, 2007; Zhou
et al, 2012).
In the present study, we demonstrate that the genetic inactivation
of Klf4 blocks the development and progression of CCM lesions and
almost abrogates the mouse mortality due to brain hemorrhage.
Furthermore, we proved that abrogation of Ccm1 in brain ECs
activates extracellular signal-regulated kinase 5 (ERK5) through the
MEKK3-MEK5 signaling axis that, in turn, upregulates KLF4. Its
transcriptional activity promotes EndMT in ECs lining the
cavernomas. KLF4 acts by increasing BMP6 that promotes SMAD-
dependent EndMT which, in turn, contributes to the development of
CCM vascular malformations and their hemorrhagic evolution.
Overall, this study describes a crucial mechanism through which
CCM vascular malformations develop and identifies novel potential
pharmacological targets to prevent the progression of this so far
incurable disease.
Results
KLF4 is a causative factor for the development and progression
of CCM lesions
As previously described (Maddaluno et al, 2013), tamoxifen-
induced postnatal and endothelial-specific Ccm1 deletion (iCCM1)
resulted in the development of several vascular lesions of venous
origin mostly concentrated in the cerebellum and in the retina that
caused 100% mortality between postnatal days 14 (P14) and 15
(P15) (Figs 1A and EV1A). KLF4 nuclear amount was strongly
increased in both the brain and retinal vasculature in iCCM1 mice in
comparison with matched controls, both in ECs lining the cavernae
of any size and in pseudo-normal vessels (Maddaluno et al, 2013)
(Figs 1B and C, and EV1B). Klf4 upregulation was an early event
during CCM pathogenesis since it appeared at P3, soon after Ccm1
gene recombination, in freshly isolated ECs from iCCM1 brains and
it remained high during the progression of the disease (Fig EV2A).
KLF4 upregulation and pattern of expression were further confirmed
in tamoxifen-inducible endothelial-specific Ccm2 (iCCM2) and Ccm3
(iCCM3) loss-of-function mice (Maddaluno et al, 2013) (Fig EV2B).
Consistently, either silencing any one of the three Ccm genes or
inducing stable gene deletion in cultured ECs resulted in Klf4 mRNA
and protein upregulation (Fig EV3A–E).
The increase in KLF4 was observed also in cultured human brain
ECs (hCMEC/D3) when Ccm1 was silenced (Fig 2A) and, most
importantly, immunohistochemical analysis of tissue biopsies of
CCM1 familial patients confirmed the increase in KLF4 nuclear
signal in ECs lining the cavernomas in comparison with normal
peri-lesion vessels (Fig 2B).
We then investigated the role of KLF4 in the development of
CCM malformations. To this purpose, we developed endothelial-
specific tamoxifen-inducible Ccm1 and Klf4 double loss-of-function
mice (iCCM1/KLF4) (Katz et al, 2005; Wang et al, 2010; Madda-
luno et al, 2013). The newborn mice were tamoxifen-injected
at P1 to induce the expression of Cre-recombinase and
▸Figure 1. KLF4 is determinant for CCM development in vivo.A Representative images of WT, iCCM1, and iCCM1/KLF4 mouse brains at P12 (n = 5 for each genotype). Scale bar: 500 lm.
B Representative confocal analysis of VE-CADHERIN (green) and KLF4 (red) in vascular lesions (dotted area) and pseudo-normal cerebellar vessels (white arrowheads) of
WT, iCCM1, and iCCM1/KLF4 mice (n = 4 in each group). VE-CADHERIN identifies ECs; DAPI visualizes nuclei. Scale bar: 50 lm.
C qRT–PCR of both Ccm1 and Klf4 expression performed on freshly isolated brain ECs derived by WT, iCCM1, and iCCM1/KLF4 mice at P12. Fold difference in gene
expression is relative to WT mice. Data are mean  SD (n = 4–5/group). A two-tailed unpaired t-test was performed. Ccm1: ***P = 0.0004; Klf4: ***P = 0.0003,
****P = 1.43E-05.
D Quantification of number and size of vascular lesions in the cerebellum of iCCM1 and iCCM1/KLF4 mice at P12. Columns represent means  SD (n = 3 for each
genotype from 2 litters). A two-tailed unpaired t-test was performed comparing iCCM1 versus iCCM1/KLF4. < 5,000 lm2: **P = 0.0018; 5–1,000 lm2: *P = 0.0117;
> 10,000 lm2: **P = 0.0019.
E Kaplan–Meier survival curve of WT, iCCM1, and iCCM1/KLF4 mice (n = 8 for each group). Mantel–Cox statistical test was performed: ***P < 0.0001.
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endothelial-specific gene ablation. The pups were analyzed within
2 weeks upon gene recombination. Ccm1 deletion was comparable
in freshly isolated brain ECs derived from iCCM1 and iCCM1/
KLF4 animals at P12 (Fig 1C). Klf4 was abrogated in the double
KO iCCM1/KLF4 pups as verified by immunofluorescence and
qRT–PCR (Fig 1B and C).
iCCM1/KLF4 mice showed a macroscopic reduction in the
number, size, and extension of the CCM vascular malformations in
the cerebellum (Fig 1A, B, and D). Quantification of the number of
cavernomas of any size revealed a 70% reduction in iCCM1/KLF4
in comparison with iCCM1 mice (Fig 1D). Abrogation of Klf4 also
reduced by 75% mouse mortality in Ccm1-deficient pups (Fig 1E).
We previously observed that iCCM1 animals developed vascular
malformations also at the periphery of the retinal vascular plexus
(Maddaluno et al, 2013) (Fig EV1A and B), in line with what was
described in 5% of familial CCM patients (Reddy et al, 2010).
Endothelial-specific Klf4 deletion did not alter retinal vasculature
formation per se (Appendix Fig S1), but significantly reduced the
area and the vascular density at the front of malformed retinal
vessels Ccm1 deficient (Fig EV1A–D), while the advancing of the
vasculature across the vitreal surface (vascular progression) was
not modified (Fig EV1E).
In conclusion, our data indicate that KLF4 is required for the
development and progression of CCM1 vascular malformations.
A
B
Figure 2. KLF4 is increased in a human brain cell line upon loss of CCM1 and in cerebral lesions of CCM1 patients.
A Left panel: Ccm1 and Klf4 relative mRNA levels in CCM1 (siCCM1) and control (siCTRL) siRNA-treated hCMEC/D3. The result is shown as fold changes in gene expression
in siCCM1-treated versus control. Data are presented as mean  SD (n = 3). A two-tailed unpaired t-test was performed. ****P < 0.00001, ####P = 1.2E-05. Right
panel: WB analysis of KLF4 amount in siCCM1- and siCTRL-treated hCMEC/D3. Tubulin is used as a loading control. These data are representative of three
independent observations.
B Immunohistochemical analysis performed on serial sections of brain tissue derived from a familial CCM1 patient. Hematoxylin and eosin (left panels), CLAUDIN5
(central panels), and KLF4 (right panels) stainings were performed in brain lesion and normal peri-lesion vessels as control brain tissue. Higher magnification images
of KLF4 staining of the boxed regions are shown. CLAUDIN5 identifies ECs and arrowheads mark endothelial KLF4-positive nuclei. Scale bar: 100 lm. These data are
representative of three independent observations.
Source data are available online for this figure.
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KLF4 induces EndMT in CCM1-null ECs
As we previously reported and extensively characterized both
in vivo and in vitro, endothelial-specific disruption of Ccm genes
induces the EndMT switch in ECs lining the cavernomas
(Maddaluno et al, 2013). Thus, the simultaneous expression of
endothelial-specific molecules (PECAM1, VE-CADHERIN, or
isolectin B4) together with typical EndMT markers was detected in
CCM1 KO ECs (Maddaluno et al, 2013 and Appendix Fig S2). To
investigate whether KLF4 had a key role in this process, we
performed Klf4 silencing in CCM1 WT and KO ECs by lentiviral
vector-mediated trasduction of shRNA. Klf4 knockdown strongly
reduced mRNA and protein amount of markers of the stem cell/
EndMT phenotype (Fig 3A and B) that were upregulated in cultured
CCM1 KO ECs. Comparable data were obtained when Ccm1 and
Klf4 LoxP-site flanked genes were concomitantly deleted by TAT-
Cre-recombinase (Fig EV4A–D and F).
In these experimental conditions, abrogation of Klf4 expression
did not prevent the decrease and disorganization of VE-Cadherin
and Claudin5, previously reported in CCM1-ablated cells (Figs 3A
and EV4B).
In the absence of Ccm1, cell transition to a mesenchymal pheno-
type is accompanied by increased proliferation and migration
(Wustehube et al, 2010; Maddaluno et al, 2013). Both parameters
were impaired by Klf4 silencing in cultured CCM1 KO ECs (Fig 3C
and D).
To investigate whether KLF4 is sufficient to promote EndMT, we
infected WT ECs in culture with a lentiviral vector expressing Klf4
(LentiKLF4) or an empty vector (Mock) as control, achieving a
threefold Klf4 induction (Fig 3E), a level of upregulation comparable
to that observed in CCM1 KO ECs. KLF4 upregulation in WT ECs
increased EndMT markers at both mRNA (Fig 3E, left panel) and
protein levels (Fig 3E, right panel), whereas it did not affect the
expression of the endothelial junction molecules as VE-cadherin and
Claudin 5 (Fig 3E, left panel).
Most importantly, in the absence of KLF4, EndMT switch was
strongly prevented both in freshly isolated brain ECs (Fig EV5A)
and in lesions of iCCM1/KLF4 mice (Fig EV5B–D).
The role of KLF4 as inducer of EndMT appears cell-context-
dependent, since in the absence of CCM1 KLF4 was increased in
ECs of different organs but the full EndMT marker upregulation was
detected only in brain ECs (Appendix Fig S3).
In the retina vasculature, KLF4 was higher in veins than in
arteries in both WT and iCCM1 mice and further increased in the
lesion (Appendix Fig S4A–C). Interestingly, ID1 expression in the
retina seemed to correlate with KLF4 (Appendix Fig S4A, B and D).
These data suggest that higher levels of KLF4 in veins may explain
the venous origin of the cavernomas.
Taken together, these results show that KLF4 upregulation is
critical to promote the EndMT switch induced by CCM1 abrogation.
However, the strength of this effect is context-dependent being
observed specifically in the brain vasculature.
KLF4 regulates BMP6-mediated signaling
Since BMP6 upregulation triggers the transcription program leading
to EndMT in Ccm1-deficient cells and mice (Maddaluno et al, 2013),
we asked whether it could be regulated by KLF4. We observed that
Klf4 silencing strongly decreased Bmp6 expression and SMAD1
phosphorylation (pSMAD1) in cultured CCM1 KO ECs (Fig 4A and
B). Immunohistochemical analysis of brain tissues confirmed BMP6
reduction in ECs lining the cavernomas of iCCM1/KLF4 mice
compared to iCCM1 animals (Fig 4C).
Since eight putative KLF4 binding sites were identified within the
murine Bmp6 promoter region at 5.0 kb and +1.0 kb from the
transcription start site (tss), we hypothesized Bmp6 as a direct tran-
scriptional target of KLF4. In ChIP assay, KLF4 binding was enriched
at the selected sites on Bmp6 promoter in CCM1 KO compared to
WT ECs, suggesting that Bmp6 is a KLF4 target gene (Fig 4D). To
demonstrate that the binding of KLF4 to Bmp6 promoter is function-
ally active, a transcriptional reporter assay was performed by co-
transfecting the Bmp6 reporter construct (generated by cloning the
promoter region enriched in KLF4 binding sites upstream of the luci-
ferase cDNA) together with an expression plasmid of a full-length
KLF4 or a mutant KLF4 lacking the DNA-binding zinc finger
domains (KLF4 ΔZnF). We found that KLF4 induced Bmp6 promoter
activity and this effect was reduced when KLF4 binding to DNA was
altered (Fig 4E).
Furthermore, both Bmp6 mRNA (Fig 5A) and pSMAD1 (Fig 5B)
were upregulated in KLF4-overexpressing cells and, by ChIP analy-
sis, KLF4 was associated with the selected sites within the Bmp6
promoter region (Fig 5C). Stable Bmp6 silencing by lentivirally
transduction of shRNA (Fig 5D) prevented the increase of both
pSMAD1 (Fig 5E) and EndMT markers induced by KLF4 in
LentiKLF4 ECs (Fig 5F).
Overall, our results demonstrate that KLF4 increases Bmp6
expression that, in turn, contributes to the EndMT program of
CCM1-null ECs.
KLF4 directly regulates the expression of some EndMT markers
We then investigated whether KLF4-induced EndMT is fully
dependent on the upregulation of BMP6 or whether KLF4 could
also have an independent and direct effect on EndMT marker
expression. To this purpose, we treated WT and KLF4 KO ECs
(Fig 6A) with recombinant BMP6 and we analyzed a set of repre-
sentative mesenchymal and stem cell markers. Although the
induction of SMAD1 phosphorylation was comparable (Fig 6B),
BMP6-induced expression of Fsp1 and Sca1, but not Id1, was
reduced in the absence of KLF4 (Fig 6C), suggesting a direct
contribution of KLF4 to the upregulation of some EndMT markers.
Several consensus sequences for KLF4 were identified in the
promoter region of murine Fsp1, Sca1, and Id1. ChIP analysis
revealed KLF4 binding to both Fsp1 (Fig 6D) and Sca1 promoters
(Fig 6E), with the binding occurring mainly in the regions located
at +0.1 kb and +0.7 kb (Fsp1) and 1.4 kb and +0.4 kb (Sca1)
from the tss, respectively. Conversely, KLF4 binding to Id1
promoter was barely detectable, suggesting that Id1, a bona fide
BMP6 target gene (Korchynskyi & ten Dijke, 2002), is not directly
regulated by KLF4 (Fig 6F). Moreover, both Fsp1 and Sca1 tran-
scriptional reporters (generated by cloning the promoter regions
enriched in KLF4 binding sites identified by ChIP upstream of the
luciferase cDNA) were strongly induced by KLF4 in a DNA-
binding-dependent manner (Fig 6G and H).
Thus besides inducing BMP6, KLF4 can also directly upregulate
some EndMT markers.
ª 2015 The Authors EMBO Molecular Medicine
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Erk5 activation mediates KLF4 upregulation and KLF4-dependent
EndMT in the absence of Ccm1
We then approached the problem of the molecular mechanism
through which loss of Ccm results in increased Klf4 expression
in the brain and retinal vasculature. ERK5 phosphorylation and
activation have been reported to promote Klf2 and Klf4 transcrip-
tion in ECs (Dekker et al, 2002; Ohnesorge et al, 2010;
Komaravolu et al, 2015). Myocyte enhanced (MEF) family of tran-
scription factors, downstream targets of ERK5, are directly
involved in pitavastatin-dependent KLF4 upregulation in HUVEC
(Maejima et al, 2014).
A
B
E
C D
Figure 3. KLF4 regulates the EndMT switch in CCM1 KO ECs.
A–D Cultured lung-derived WT and CCM1 KO ECs were lentivirally transduced with shRNA directed to either Klf4 (shKLF4) or control sequence (shCTRL). (A) qRT–PCR of
mesenchymal (Fsp1, Id1), stem cell-like (Sca1), and endothelial markers (VE-cadherin and Claudin5) in WT shCTRL, WT shKLF4, CCM1 KO shCTRL, and CCM1 KO
shKLF4 ECs. Data are mean  SD (n = 3). Fold difference in gene expression is relative to WT shCTRL ECs. A two-tailed unpaired t-test was performed. Klf4:
****P < 0.00001, ***P = 0.0008, **P = 0.007; Fsp1: ***P = 0.0001, ****P = 3.9E-05, ###P = 0.0002; Sca1: ***P = 0.0001, ****P < 0.00001; Id1: ***P = 0.0001;
Ve-cadherin: ***P = 0.0001; Claudin5: ****P = 1.37E-05. (B) WB of EndMT markers in WT shCTRL, WT shKLF4, CCM1 KO shCTRL, and CCM1 KO shKLF4 ECs. Vinculin
is the loading control. These data are representative of three independent observations. (C) Proliferation rate of WT shCTRL, WTshKLF4, CCM1 KO shCTRL, and
CCM1 KO shKLF4 ECs cultured for 5 days. Columns represent mean  SD (n = 8). A two-tailed unpaired t-test was performed. 3 days of culture: ***P = 0.0001,
**P = 0.0045, ##P = 0.0017; 5 days of culture: ***P = 0.0001, **P = 0.0029, ##P = 0.0040. (D) Migration rate measured in a wound assay of WT shCTRL, CCM1 KO
shCTRL, and CCM1 KO shKLF4 ECs. Mean  SD is shown (n = 6). A two-tailed unpaired t-test was performed. ***P = 0.0004, ###P = 0.0009.
E Cultured lung-derived WT ECs were lentivirally transduced with a full-length murine Klf4 (LentiKLF4) or empty vector (Mock). qRT–PCR (left panel) and WB (right
panel) of EndMT markers in Mock and LentiKLF4 ECs. qRT–PCR data are mean  SD (n = 3) and the fold changes are relative to Mock ECs. A two-tailed unpaired
t-test was performed. **P = 0.002, ***P = 0.0007, ###P = 0.0001. WB results are representative of three independent observations. Tubulin is the loading control.
Source data are available online for this figure.
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We found that ERK5 phosphorylation was increased in freshly
isolated brain-derived ECs of iCCM1 mice in comparison with
matched controls (Fig 7A). Accordingly, ERK5 phosphorylation was
higher in cultured ECs upon Ccm1 ablation (Figs 7B and C, and
EV4E and F).
To investigate whether ERK5 activation was responsible for the
upregulation of both KLF4 and EndMT marker expression in the
absence of CCM1, we transfected WT ECs with siRNAs directed to
Erk5 and Ccm1. The downregulation of ERK5 strongly prevented
KLF4 upregulation in Ccm1-silenced ECs (Fig 7B). Similarly, the
treatment of cultured CCM1 KO ECs with XMD8-92, a specific ERK5
inhibitor (Yang et al, 2010; Komaravolu et al, 2015), strongly inhib-
ited KLF4 overexpression, Bmp6 upregulation, SMAD1 phosphoryla-
tion, and EndMT marker acquisition (Figs 7C–E and EV4F).
Activated ERK5 promoted KLF4 upregulation through MEF2A and
MEF2C transcription factors in CCM1 KO ECs, since both Mef2A
and Mef2C knockdown in CCM1 KO ECs reduced significantly
KLF4 (Fig 7F top and middle panels, respectively). Conversely,
Mef2D silencing did not modify KLF4 amount (Fig 7F bottom panel).
To establish ERK5-mediated KLF4 upregulation and KLF4-
dependent EndMT as common molecular nodes in CCM, we analyzed
ERK5 activation, KLF4 amount, and EndMT marker expression in
WT, CCM2 KO, or CCM3 KO ECs treated with XMD8-92 or vehicle as
control. We found that in ECs null for either Ccm2 or Ccm3 ERK5
phosphorylation was increased (Fig EV3B and D, respectively).
Furthermore, the treatment of cultured CCM2 KO and CCM3 KO ECs
with XMD8-92 strongly inhibited KLF4 overexpression, Bmp6
upregulation and EndMT marker acquisition (Fig EV3B–E).
MAPK/ERK kinase kinase 3 (MEKK3), previously identified as a
CCM2 and CCM1 binding partner in the osmosensing complex
(Uhlik et al, 2003; Zhou et al, 2015), activates MAPK/ERK kinase 5
(MEK5) that, in turn, phoshorylates ERK5 (Kato et al, 1997; Sohn
et al, 2005). We therefore explored the possibility that the lack of
CCM might increase Klf4 expression through the MEKK3-MEK5-
ERK5 signaling axis. Both Mekk3 (Fig 8A) and Mek5 (Fig 8B) silenc-
ing, as well as the treatment of cultured CCM1 WT and KO ECs with
BIX-02189 (Fig 8C), a specific MEK5 inhibitor (Tatake et al, 2008),
strongly reduced ERK5 phosphorylation and KLF4 amount in the
absence of CCM1.
Thus, Ccm gene ablation results in increased MEKK3-MEK5-
dependent ERK5 phosphorylation responsible for KLF4 upregulation
and KLF4-dependent EndMT.
Discussion
We report here that the transcription factor KLF4 is a crucial deter-
minant of the development of CCM. In human vascular lesions and
in mice deficient of anyone of the three Ccm genes, KLF4 is strongly
upregulated in ECs lining the cavernomas. Most importantly, Klf4
genetic inactivation blocks the development of the vascular lesions
and mortality. To our knowledge, this is the first targeting condition
that essentially abolishes the 100% mortality observed in iCCM1
mice due to brain hemorrhage.
The mechanism of action of KLF4 in inducing CCM malforma-
tions is complex and the data reported here define some of
the molecular steps involved (Fig 8D). As previously shown
(Maddaluno et al, 2013), the formation of cavernomas is linked to
the transition of ECs lining the malformations to a mesenchymal
phenotype (EndMT switch). In the absence of CCM1, EndMT is
mediated by the increase of endogenous Bmp6 that we show here to
be induced by KLF4. Klf4 expression increases soon after Ccm
ablation and remains high in ECs lining the CCM lesions. KLF4
induction could therefore contribute to the induction and progres-
sion of the disease by upregulating BMP6.
KLF4 can also induce EndMT by binding directly to the promot-
ers of some EndMT markers (Sca1 and Fsp1). Intriguingly, the
promoter regions of the EndMT markers that showed a higher bind-
ing affinity for KLF4 are surrounded by putative SMAD-binding
sites. Since pSMADs bind weakly to target gene promoters (Shi
et al, 1998), it is possible that their DNA binding is reinforced
through the association with KLF4, adding a further level of regula-
tion of SMAD activity by KLF4 (Li et al, 2010).
KLF4 has pleiotropic functions in EC biology. It is widely consid-
ered a vascular protective factor due to its ability to activate specific
transcriptional programs with anti-inflammatory, anticoagulant, and
antioxidant roles in the endothelium (Hamik et al, 2007; Zhou et al,
2012; Shatat et al, 2014). However, recent publications have associ-
ated KLF4 also with endothelial diseases, since it can promote
sprouting angiogenesis by regulating Notch pathway and it is
upregulated in several pathological conditions (Chen et al, 2014;
Hale et al, 2014; Magrini et al, 2014). Although KLF4 may act either
as an inducer or a suppressor of cell proliferation in different cell
types (McConnell & Yang, 2010), several publications reported KLF4
as a promoter of endothelial cell growth (Hale et al, 2014; Wang
et al, 2015). These data are consistent with the fact that high KLF4
Figure 4. KLF4 increases Bmp6 expression and SMAD1 phosphorylation in ECs.
A qRT–PCR of Bmp6 expression in WT shCTRL, WT shKLF4, CCM1 KO shCTRL, and CCM1 KO shKLF4-cultured ECs. Data represent the mean  SD (n = 3). Fold changes
are relative to CCM1 KO shCTRL ECs. A two-tailed unpaired t-test was performed. ****P < 0.00001.
B WB of pSMAD1 and SMAD1 in WT shCTRL, WT shKLF4, CCM1 KO shCTRL, and CCM1 KO shKLF4 ECs. pSMAD1/SMAD1 ratio normalized over tubulin was quantified by
densitometry scan. These data are representative of three independent observations.
C Immunohistochemical analysis of PECAM1 (left panels) and BMP6 (central panels) performed on serial sections of cerebellum derived from WT, iCCM1, and iCCM1/
KLF4 mice at P12. Higher magnification images of the boxed regions are shown in the right panels. Black arrowheads mark ECs and dotted area indicates the
Purkinje cell layer used as a positive control of the staining. Scale bar: 100 lm. These data are representative of three independent observations (n = 3 for each
genotype).
D ChIP analysis of KLF4 binding to Bmp6 promoter. Putative KLF4 binding sites identified by MatInspector are indicated. The levels of DNA are normalized to input.
Columns are mean  SD of triplicates from a representative experiment out of three.
E Transcriptional reporter assay performed in HEK-293 cells transfected with Bmp6 promoter reporter plasmid together with an empty vector, a full-length KLF4 or a
mutant KLF4 lacking the DNA-binding zinc finger domains (KLF4 ΔZnF). Red boxes in the picture indicate KLF4 binding sites validated by ChIP. Fold change in the
Bmp6 promoter activity is relative to empty vector-transfected cells. Data are mean  SD (n = 3). A two-tailed unpaired t-test was performed. ****P < 0.00001,
####P = 5.8E-05.
Source data are available online for this figure.
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amount in CCM1 KO ECs results in increased cell growth and Klf4
silencing lowers cell proliferation in both WT and CCM1-null ECs.
A context-dependent function of KLF4 could explain its protec-
tive versus pathogenic role in different type of vessels. While it
confers vascular protection to atherothrombosis and pulmonary
arterial hypertension when is upregulated in arteries (Zhou et al,
2012; Shatat et al, 2014), it may play a causative role in the develop-
ment of venous-derived CCM cavernomas (Boulday et al, 2011;
Maddaluno et al, 2013). Albeit we still do not know the molecular
basis of these discrepancies, it is conceivable that the interaction
with cell-specific transcription factors or differences in kinetics and
levels of expression may modulate the response of ECs to KLF4. In
this direction, it is noticeable that the levels of KLF4 are higher in
retinal veins than in arteries in both physiological condition and
upon Ccm1 deletion. The cell specificity of KLF4-dependent biologi-
cal responses is also underlined by the observation that a compara-
ble increase in KLF4 induced in ECs of different organs by loss of
Ccm1 resulted in a full EndMT switch only in brain-derived ECs.
Thus, cell context-dependent function of KLF4 could be placed in a
central position in promoting either vascular health or disease.
In the present paper, we also investigated the mechanism
through which the absence of CCM may increase KLF4. Laminar
flow through ERK5 activation is a well-known inducer of Klf4
expression and activity (Ohnesorge et al, 2010; Clark et al, 2011).
However, we observed a marked increase of Klf4 in CCM-null ECs
in the absence of flow. CCM complex disruption in the endocardium
A B C
D E F
Figure 5. KLF4 promotes EndMT through BMP6 upregulation.
A qRT–PCR of Bmp6 in Mock and LentiKLF4-cultured ECs. Data are mean  SD (n = 3). Fold changes are relative to Mock ECs. A two-tailed unpaired t-test was
performed. **P = 0.0034.
B WB of pSMAD1 and SMAD1 in Mock and LentiKLF4 ECs. Vinculin is the loading control. pSMAD1/SMAD1 ratio normalized over vinculin was quantified by
densitometry scan. These data are representative of three independent observations.
C ChIP of KLF4 interaction with Bmp6 promoter in Mock and LentiKLF4 ECs. Putative KLF4 binding sites identified by MatInspector are indicated. The levels of DNA
are normalized to input. Columns are mean  SD of triplicates from a representative experiment out of three.
D–F Mock and LentiKLF4-cultured ECs were lentivirally transduced with shRNA directed to either Bmp6 (shBMP6) or control sequence (shCTRL). (D) qRT–PCR analysis
of Bmp6 in Mock shCTRL, Mock shBMP6, LentiKLF4 shCTRL, and LentiKLF4 shBMP6 ECs. qRT–PCR data represent the mean  SD (n = 3) and the fold changes are
relative to Mock shCTRL ECs. A two-tailed unpaired t-test was performed. ***P = 0.0008, **P = 0.004, ##P = 0.003. WB of pSMAD1 and SMAD1 (E) or EndMT
markers (F) in Mock shCTRL, Mock shBMP6, LentiKLF4 shCTRL, and LentiKLF4 shBMP6-cultured ECs. pSMAD1/SMAD1 ratio was quantified as in (B). These WB data
are representative of three independent observations. Tubulin is the loading control. The fold changes of FSP1, SCA1, and ID1 normalized over tubulin were
quantified by densitometry scan. These WB data are representative of three independent observations.
Source data are available online for this figure.
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Figure 6. KLF4 directly regulates some EndMT marker expression.
A qRT–PCR (left panel) and WB (right panel) analyses of KLF4 in cultured lung WT and KLF4 KO ECs. qRT–PCR data represent the mean  SD (n = 3) and the fold
changes are relative to WT ECs. A two-tailed unpaired t-test was performed. ***P = 0.0006. GAPDH is the loading control in WB. These WB data are representative
of three independent observations.
B WB of pSMAD1 and SMAD1 in WT and KLF4 KO ECs left untreated or treated with recombinant BMP6 for 4 h. pSMAD1/SMAD1 ratio normalized over GAPDH was
quantified by densitometry scan. These WB data are representative of three independent observations.
C qRT–PCR of Fsp1, Sca1, and Id1 in WT and KLF4 KO ECs stimulated with BMP6 for 96 h. qRT–PCR data are mean  SD (n = 3). Fold changes in gene expression in
BMP6-treated versus untreated ECs. A two-tailed unpaired t-test was performed. **P = 0.0032, ***P = 0.0007.
D–F ChIP analysis of KLF4 binding to the promoters of Fsp1 (D), Sca1 (E), and Id1 (F) in WT and CCM1 KO cultured ECs. The positions of the putative KLF4 binding sites
identified with MatInspector in the promoters of the genes analyzed are indicated. The levels of DNA are normalized to input. Columns are mean  SD of
triplicates from a representative experiment out of three performed.
G, H Transcriptional reporter assays performed in HEK-293 cells transfected with either Fsp1 (G) or Sca1 (H) promoter reporter plasmid together with an empty vector,
KLF4 or KLF4 ΔZnF. In the schematics, red boxes indicate KLF4 binding sites validated by ChIP, while grey boxes indicate KLF4 binding sites not validated by ChIP.
Fold change in the promoter activity is relative to empty vector-transfected cells. Data are mean  SD (n = 3). A two-tailed unpaired t-test was performed.
****P < 0.00001.
Source data are available online for this figure.
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Figure 7. In the absence of CCM1 increased ERK5 phosphorylation is responsible for KLF4 upregulation and KLF4-dependent EndMT.
A WB of phoshorylated ERK5 (pERK5) and total ERK5 in freshly isolated brain ECs from WT (n = 2) and iCCM1 (n = 4) mice from two different litters at P12. VE-PTP
measures the endothelial content and vinculin is the loading control. pERK5/ERK5 ratio normalized over vinculin and VE-PTP was quantified by densitometry scan.
B WB of pERK5, ERK5, and KLF4 in cultured lung-derived WT ECs either Ccm1 (siCCM1) or control (siCTRL) siRNA-treated alone or in combination with two siRNA
targeting Erk5 (siERK5#1,2). pERK5/ERK5 ratio normalized over vinculin is indicated. These data are representative of three independent observations.
C–E Treatment of cultured lung-derived WT and CCM1 KO ECs with either 5 lM of XMD8-92 or the vehicle (72 h). (C) WB analysis of pERK5, ERK5, and KLF4. pERK5/
ERK5 ratio was quantified as in (B). (D) Left panel: evaluation of pSMAD1 and SMAD1 protein levels. pSMAD1/SMAD1 ratio normalized over vinculin is shown. These
data are representative of three independent observations. Right panel: qRT–PCR of Bmp6. The data represent the mean  SD (n = 3). Fold changes are relative to
vehicle-treated CCM1 KO ECs. A two-tailed unpaired t-test was performed. **P = 0.001, *P = 0.01. (E) Representative WB of EndMT markers (one out of three
performed). Tubulin is the loading control.
F qRT–PCR analysis of Klf4, Mef2A, Mef2C, and Mef2D (left panels) and WB of KLF4 (right panels) in cultured WT and CCM1 KO ECs treated with either control siRNA
(siCTRL) or siRNA directed to any of Mef2A (upper panels), Mef2C (central panels), or Mef2D (lower panels). qRT–PCR data represent the mean  SD (n = 3) and the
fold changes are relative to WT siCTRL ECs. A two-tailed unpaired t-test was performed. Upper panels: ***P = 0.0002, ###P = 0.0005, ****P = 4.09E-05,
**P = 0.001; central panels: ***P = 0.0005 (WT siCRTL vs WT siMEF2C), ***P = 0.0006 (KO siCRTL vs KO siMEF2C), ###P = 0.0001, ****P < 0.00001, **P = 0.007;
lower panels: ****P = 5.6E-05 (WT siCRTL vs WT siMEF2D), ****P = 1.53E-05 (KO siCRTL vs KO siMEF2D), ####P = 3.1E-05. For WB, vinculin is used as a loading
control and data are representative of three independent observations.
Source data are available online for this figure.
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Figure 8. MEKK3-MEK5-dependent ERK5 phosphorylation is responsible for KLF4 upregulation.
A Left panel: WB analysis of pERK5, ERK5, KLF4, and MEKK3 in WT and CCM1 KO ECs treated with either two different siRNAs against Mekk3 (siMEKK3 #1 and siMEKK3
#2) or a control sequence (siCTRL). Both pERK5/ERK5 ratio and KLF4 amount normalized over vinculin were quantified by densitometry scan. WB results are
representative of three independent observations. Right panel: qRT–PCR of Klf4 in WT and CCM1 KO ECs treated with two different siRNAs directed to Mekk3
(siMEKK3 #1 and siMEKK3 #2) or a control sequence (siCTRL). qRT–PCR results are shown as mean  SD (n = 3), and fold changes are relative to siCTRL-treated WT
ECs. A two-tailed unpaired t-test was performed. ***P = 0.0002, **P = 0.002, ****P = 2.5E-05, ####P = 3.1E-05, ###P = 0.0007.
B WB analysis of pERK5, ERK5, KLF4, and MEK5 (left panel) and qRT–PCR of Klf4 (right panel) in WT and CCM1 KO ECs treated with a siRNA against MEK5 or a control
sequence (siCTRL) quantified as in (A). **P = 0.0035, ****P < 0.00001, ####P = 3.5E-05.
C WB analysis of pERK5, ERK5, and KLF4 (upper panel) and qRT–PCR of Klf4 (lower panel) in WT and CCM1 KO ECs treated with BIX-02189 or vehicle for 48 h quantified
as in (A). Fold changes are relative to vehicle-treated WT ECs. A two-tailed unpaired t-test was performed. ***P = 0.0002, ****P = 2.1E-05.
D Schematic model of KLF4 activity and regulation during CCM pathogenesis.
Source data are available online for this figure.
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modulates the MEKK3-MEK5-ERK5 axis to upregulate Klf4 and Klf2
expression resulting in mid-gestation heart failure (Zhou et al,
2015). MEKK3, identified as a CCM2 binding partner in the
osmosensing complex (Uhlik et al, 2003), activates MEK5 that, in
turn, through ERK5 dual phosphorylation, induces transcription
factors MEF2A, MEF2C, and MEF2D to regulate their target genes
(Kato et al, 1997; Sohn et al, 2005).
In agreement with these reports, we found that MEKK3-MEK5
axis promotes ERK5 activation upon loss of CCM1 and inhibition of
ERK5 prevents KLF4 upregulation and EndMT induction in cultured
CCM1 KO ECs. These data support the concept that ERK5 is a key
regulator of Klf4 expression after CCM complex disruption. Impor-
tantly, ERK5-dependent KLF4 upregulation is induced by inactiva-
tion of any one of the three Ccm genes consistent with the
comparable phenotype observed in patients.
Phosphorylated ERK5 promoted Klf4 expression largely through
MEF2A and MEF2C transcriptional activity. However, since a
complete KLF4 downregulation was not observed when these two
transcription factors were silenced, either ERK5 alone or other ERK5
downstream transcription factors could be responsible for KLF4
upregulation (Nithianandarajah-Jones et al, 2012). Moreover, since
several signaling pathways are reported to contribute to CCM, it
would interesting to investigate whether other transcription factors
could have a crosstalk with the MEKK3-MEK5-ERK5-MEF2-KLF4
axis during the development and progression of cavernomas (Goitre
et al, 2010; Stockton et al, 2010; Faurobert et al, 2013; Bravi et al,
2015; Gibson et al, 2015).
KLF2 has a causative role in the cardiac malformations observed
in the absence of CCM in mouse and zebra fish embryos. In these
models, KLF2 is responsible for both digestion of the cardiac jelly
(Zhou et al, 2015) and increased angiogenesis due to b1integrin–
KLF2-egfl7 signaling pathway (Renz et al, 2015). In our CCM
disease model, we found that Klf2 was upregulated in freshly
isolated brain-derived CCM1-null ECs or in cultured CCM1 KO ECs
(data not shown), supporting the idea of a possible cooperation
between KLF2 and KLF4. However, although these two transcription
factors have many common targets, they still exhibit specificity due
to individual differences in their affinities for jointly regulated
promoters. The lack of a fully overlapping biological role of KLF2
and KLF4 is also demonstrated by the different phenotype of the
respective null mice. While Klf2-null mice exhibit abnormal blood
vessel formation resulting in embryonic hemorrhage and death
(Kuo et al, 1997), Klf4-null mice die within 1 day after birth due to
loss of skin barrier function (Segre et al, 1999). The relative contri-
bution of KLF2 to the development of CCM remains an open ques-
tion and requires future studies, since Klf2 was not further
upregulated upon Klf4 ablation and apparently did not compensate
for the lack of KLF4 in inducing EndMT (data not shown).
Taken together, the data presented here demonstrate that KLF4 is
a master regulator of EndMT in CCM pathology; thus, the inhibition
of Klf4 expression may have a therapeutic role in limiting CCM
appearance and progression. Transcription factors are considered,
in general, “undruggable agents”. Indeed, KLF4 is a member of the
large family of Kruppel-like factors that are highly homologous shar-
ing a triple zinc finger DNA-binding domain (McConnell & Yang,
2010). The functions of the KLF family members can be exclusive or
in some cases overlapping and redundant, compensating for one
another and this might impair the efficacy of a possible therapy
based on specific chemical compounds (Tetreault et al, 2013).
Moreover, possible adverse effects such as increased sensitivity to
inflammation and atherosclerosis should be considered. The use of
either KLF4 or ERK5 bound to nanoparticles targeting CCM vascular
lesions may be a more specific approach in the future.
Materials and Methods
Antibodies
For Western blotting and immunostainings, the following antibodies
were used: VE-CADHERIN rat (550548, BD Biosciences); VE-
CADHERIN goat (sc-6458, Santa Cruz); PECAM1 hamster
(MAB1398Z, Millipore); PECAM1 rat (553370, BD); PECAM1 rabbit
(ab28364, Abcam); mKLF4 goat (AF3158, R&D); hKLF4 goat
(AF3640, R&D); FSP1 rabbit (07-2274, Millipore); ID1 rabbit (BCH-
1/37-2, BIOCHECK); SCA1 rat (ab51317, Abcam); hCLAUDIN5
rabbit (ab53765, Abcam); pSMAD1/5 rabbit (9516, Cell Signaling);
SMAD1 rabbit (9644, Cell Signaling); Glucose transporter type 1
(GLUT1) rabbit (RB9052P1, Thermo Scientific); ERK5 rabbit
(07-039, Upstate); VE-PTP rabbit (produced and purified by New
England Peptide); MEKK3 rabbit (5727, Cell Signaling); MEK5
mouse (610957, BD); BMP6 sheep (LS-C150156, LS-BIO); GAPDH
mouse (SC-32233, Santa Cruz); tubulin mouse (T9026, Sigma);
vinculin mouse (V9264, Sigma); horseradish peroxidase (HRP)-
linked anti-mouse, anti-rat, and anti-rabbit (Cell Signaling); and
HRP-linked anti-goat (Promega). Biotin-conjugated isolectin B4
(Vector Lab) was used to identify retinal vasculature. ALEXA
FLUOR 488, 555, and 647 donkey secondary antibodies were from
Life Technologies.
Mouse lines
Mice were all bred on a C57BL/6 background. Ccm1fl/fl, Ccm2fl/fl,
and Ccm3fl/fl mouse strains were already described (Boulday et al,
2011; Maddaluno et al, 2013; Bravi et al, 2015). Klf4fl/fl mice (Katz
et al, 2005) were kindly donated by G.K. Owens. The Cdh5(PAC)-
CreERT2 mouse line (Wang et al, 2010) was kindly provided by
R.H. Adams. Rosa26-Stopfl-LacZ mice (Srinivas et al, 2001) have
been kindly donated by S. Casola. To obtain the iCCM1 mice, Cdh5
(PAC)-CreERT2 animals were first bred with the Ccm1fl/fl mouse
strain to obtain tamoxifen-inducible endothelial-specific expression
of Cre-recombinase and Ccm1 gene recombination. The Cdh5(PAC)-
CreERT2; Ccm1fl/fl mice were then crossed with Rosa26-Stopfl-LacZ
animals to monitor the activity of Cre-recombinase through the
expression of enhanced yellow fluorescent protein (EYFP). To
generate double iCCM1/KLF4 mice, Cdh5(PAC)-CreERT2; Ccm1fl/fl;
Rosa26-Stopfl-LacZ mice were crossed with Klf4fl/fl animals. Dele-
tion of floxed exons by Cre-recombinase produces loss of function.
Both iCCM2 and iCCM3 mice were derived as described for iCCM1
animals. iKLF4 mice were generated by crossing Cdh5(PAC)-
CreERT2 mice with Klf4fl/fl animals. For tamoxifen-induced gene
ablation, tamoxifen (T5648, Sigma) was dissolved in corn oil-10%
ethanol at 10 mg/ml and then further diluted at 2 mg/ml in corn oil
(Pitulescu et al, 2010). Pups of the strains indicated in each experi-
mental procedure, without any gender distinction, were injected at
P1 with an intragastric injection of 100 lg (Pitulescu et al, 2010)
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and analyzed within 13 days from the gene recombination. The
number of mice of each genotype analyzed in each experiment was
specified in the figure legends. All the mouse strains were housed in
specific pathogen-free conditions.
Endothelial cell isolation and culture
Cultured WT, CCM1 KO, CCM2 KO, CCM3 KO, and KLF4 KO lung-
derived ECs obtained from the respective floxed mouse strains (see
mouse line paragraph), as well as brain microvascular fragments
from WT, Ccm1fl/fl, and Ccm1fl/flKlf4fl/fl mice, were derived and
cultured following standard protocols already used in different
publications from our laboratory and other vascular biology groups
(Bussolino et al, 1991; Calabria et al, 2006; Liebner et al, 2008;
Anderberg et al, 2013). Lung-derived ECs were isolated from
the lung of two-month-old mice upon organ dissection and
disaggregation with collagenase A (1.5 mg/ml; Roche) and DNase
(25 lg/ml; Roche) in DMEM and immortalized with polyoma
middle T antigen. Mouse brain microvascular fragments were recov-
ered by brains of two-month-old mice rolled on Whatman 3MM
chromatography blotting paper to remove the meninges, triturated,
and digested 1 h at 37°C with 0.75% type 2 collagenase (Worthing-
ton Biochemical Corp.). The pellet was resuspended in a 25% w/v
BSA solution and centrifuged for 20 min at 2,600 rpm at 4°C to
obtain a microvessel-enriched cell pellet. Then, the pellet was
further digested in 10 mg/ml collagenase/dispase (Roche) and
1 lg/ml DNase I (Roche) for 15 min at 37°C. Capillary fragments
were seeded in culture medium and selected for puromycin
(4 lg/ml) resistance for 2 days. In vitro staining of endothelial
cell-specific molecules has been extensively performed in these EC
monolayers of different origin, showing that endothelial cultures are
100% pure (Maddaluno et al, 2013). Ccm1, Ccm2, and Klf4 floxed
genes were ablated by treating cultured ECs with TAT-Cre-recombi-
nase in vitro (Liebner et al, 2008). Recombination of the floxed
Ccm3 gene was induced by treating the cells at culture day 1 with
the AdenoCre viral vector, as previously described (Cattelino et al,
2003). Immortalized cerebral microvascular EC of human origin
hCMEC/D3 ECs were provided by P.O. Couraud (Weksler et al,
2005). For ex vivo experiments, freshly isolated Pecam1+ brain-
derived ECs from iCCM1, iCCM1/KLF4 mice, and matched controls
(P12) were derived and processed as previously described
(Maddaluno et al, 2013) without to be exposed to any culture condi-
tion. In order to obtain both lung- and spleen-derived Pecam1+ ECs
from iCCM1 and matched controls, the organs were disaggregated
with collagenase A plus DNase (1.5 mg/ml and 25 lg/ml, respec-
tively; Roche) for 2 h at 37°C and passed through a 70-lm cell
strainer before to be incubated for 45 min at 4°C with anti-mouse
Pecam1-covered dynabeads. Heart-derived Pecam1+ ECs from the
same animals were recovered by incubating minced hearts with type I
collagenase (2 mg/ml, Sigma) for 45 min at 37°C. A trituration of
the heart suspension using a 30-cc syringe is required before pipet-
ting the cell suspension through a 70-lm cell strainer and loading it
on anti-mouse Pecam1-covered dynabeads.
Cell treatments
XMD8-92 (SelleckBio) and BIX-02189 (SelleckBio) were dissolved in
dimethylsulfoxide (DMSO). Confluent monolayers of ECs were
grown in complete media (MCDB-131 with 20% FBS) and treated
daily with either 5 lM XMD8-92 (for 72 h), 10 lM BIX-02189 (for
48 h), or vehicle only. For BMP6 (R&D) treatment, ECs were grown
in MCDB-131 with 5% FBS and stimulated (100 ng/ml) either for
4 h in order to analyze SMAD1 phosphorylation or for 96 h for
EndMT marker evaluation.
Production of lentiviruses
Both shRNAs against murine Klf4 and Bmp6 and control non-
targeting shRNA cloned into pLKO.1 puro-based lentiviral vector
were purchased from Sigma-Aldrich (St Louis, MO, USA,
TRCN0000238250 and TRCN0000065652). The cDNA coding for the
wild-type mouse Klf4 was obtained by GeneCopoeia (Rockville,
USA) and subcloned into the lentiviral expression vector pLenti-III-
HA (provided by abm, Richmond, BC, Canada) using XhoI and
EcoRI restriction sites (Promega, Fitchburg, WI, USA). The lentiviral
particles were produced in 293T cells using a four-plasmid transfec-
tion system mediated by calcium phosphate, as previously described
(Taulli et al, 2005). Lentivirus-containing supernatants were
collected 48 and 72 h after transfection, passed through a 0.45-lM
filter, and concentrated using PEG. Two consecutive cycles of
lentiviral infection were carried out in the presence of polybrene
followed by selection with 3 lg/ml puromycin for 72 h and mainte-
nance with 1.5 lg/ml puromycin.
Cell transfection and RNA interference
To perform RNA interference, the following siRNA were used:
Stealth RNAi directed to mouse Ccm1 (MSS294386, Life Technolo-
gies), Stealth RNAi directed to human CCM1 (MSS234455, Life Tech-
nologies), ON-TARGET plus SMART pool directed to mouse Ccm2
(L-057315-00-0005, Dharmacon), Stealth RNAi directed to mouse
Ccm3 (MSS249998, Life Technologies), Stealth RNAi directed to
mouse Erk5 (siERK5#1 MSS215825 and siERK5#2 MSS215827, Life
Technologies), Stealth RNAi directed to mouse Mek5 (MSS215820),
Stealth RNAi directed to mouse Mekk3 (siMEKK3#1 MSS218528 and
siMEKK3#2 MSS218529), Stealth RNAi directed to mouse Mef2A
(MSS206607), Stealth RNAi directed to mouse Mef2C (MSS206611),
Stealth RNAi directed to mouse Mef2D (MSS247431), negative
control siRNA Medium GC content (12935-300, Life Technologies),
and ON-TARGET plus siControl (D-001810-10, Dharmacon). Cells
were transfected with 40 nM siRNA oligonucleotides for 5 h in Opti-
mem using Lipofectamine 2000 (Life Technologies) in accordance
with the manufacturer’s instructions and as previously described
(Lampugnani et al, 2010).
Western blotting
For Western blot analysis, cells were lysed using a boiling modified
Laemmli sample buffer (2% SDS, 20% glycerol, and 125 mM Tris–
HCl, pH 6.8). Protein concentration was estimated using the BCA
Protein Assay Kit (Pierce). Equal amounts of proteins were sepa-
rated by SDS–PAGE and transferred to a Protran nitrocellulose
membrane 0.2-lm pores (Whatman). Membranes were blocked for
1 h at room temperature (RT) and, then, incubated with primary
antibody (overnight at 4°C) and HRP-linked secondary antibodies
(1 h at RT) in Tris-buffered saline-Tween (TBST) containing 5%
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BSA. Specific signals were detected by chemiluminescence system
(GE Healthcare) using ChemiDoc XRS gel imaging system (Bio-Rad).
All Western blots shown in figures are representative experiments
out of three performed. The predicted molecular weights are indi-
cated in the figures.
qRT–PCR analysis
Total RNA was isolated by extraction with the RNeasy mini kit
(Qiagen). Isolation of RNA from freshly isolated Pecam+ brain-
derived ECs was performed using RNeasy micro kit (Qiagen).
About 1 lg RNA was reverse-transcribed with random hexamers
(High Capacity cDNA Archive kit; Applied Biosystems). cDNA was
amplified with the TaqMan Gene Expression assay (Applied Biosys-
tems) and an ABI/Prism 7900 HT thermocycler. For any sample,
the expression level normalized to both the housekeeping genes
encoding 18S and hypoxanthine phosphoribosyltransferase 1
(Hprt1) was determined by the comparative threshold cycle (Ct)
method as described previously (Spagnuolo et al, 2004). mRNA
levels of the several transcripts of interest obtained by freshly
isolated tissue-derived ECs were normalized for endothelial cell
content using Pecam1 amount.
Cell migration assay
Wound healing assay was used to measure cell migration. Confluent
EC monolayers were starved overnight and then manually wounded
with a pipette tip. Cells were then washed with phosphate-buffered
saline (PBS) and incubated at 37°C in complete media. Cell migra-
tion was examined by crystal violet staining (0.5% crystal violet in
20% methanol) and phase-contrast microscopy. Quantification of
migration was performed by ImageJ software.
Cell proliferation assay
Cell proliferation assay was performed as already described
(Giampietro et al, 2012). Briefly, cells were plated at density of
4,000 cells/well in 96-well plates and analyzed at the indicated time
points by crystal violet staining (0.1% crystal violet in 20%
methanol). The optical density of the dye was measured using a
Victor Microplate reader at the wavelength of 590 nm.
Transcription factor binding site analysis and ChIP assay
The identification of KLF4 consensus binding sequences on the
putative Fsp1, Sca1, Id1, Bmp6 promoter regions was performed
using the program MatInspector (Cartharius et al, 2005) and analyz-
ing 5.0 kb upstream to 1.0 kb downstream from tss. ChIP assay was
performed as already reported (Corada et al, 2010; Taddei et al,
2008). Chromatin extracts containing 1 mg of DNA fragments with
an average size of 500 bp were incubated with either 10 mg KLF4
antibody or IgG control overnight at 4°C in the presence of protein
G-covered magnetic beads (Life Technologies). Bound DNA frag-
ments were eluted and amplified by qRT–PCR using primers
flanking the indicated promoter regions listed in Appendix Table S1.
For qRT–PCR analyses, DNA was diluted with specific primers
(10 mM each) to a final volume of 25 ll in SYBR green Reaction
Mix (PerkinElmer).
Transcriptional reporter assay
HEK-293 cells were plated in 24-well plates and transfected for 5 h
in Optimem using Lipofectamine 2000 (Life Technologies) with the
reporter plasmids (PGL3 basic vector) expressing the luciferase
cDNA under the control of a promoter portion, identified as
enriched in KLF4 binding sites by ChIP, of either Fsp1 (1.8 kb), Sca1
(2.1 kb), or Bmp6 (2.3 kb). The sequences of the primers used to
clone the promoter regions of Fsp1, Sca1, and Bmp6 are listed in
Appendix Table S2. pCDNA3 expression vectors containing either
full-length KLF4 or a mutant KLF4 lacking the DNA-binding zinc
finger domains (KLF4 ΔZnF) (kind gifts of Mukesh Jain; Feinberg
et al, 2005) were transfected where indicated. Renilla-expressing
plasmid was used as an internal control to correct for transfection
efficiency. DualLuciferase Reporter Assay System (Promega) was
used to measure firefly and renilla luciferase activities 30 h upon
transfection with a GloMax luminometer (Promega).
Brain tissue histology and immunofluorescence
Mouse brains were dissected, embedded in Tissue-Tek OCT (Sakura),
and snap-frozen. Ten-micrometer-thick sections were fixed in 4%
paraformaldehyde (PAF) and subjected to immunostaining. The
slides were blocked for 3 h at RT with PBS containing 2% BSA, 5%
donkey serum, and 0.05% Triton X-100 (blocking solution). Incuba-
tion with primary (overnight at 4C) and secondary (3 h at RT) anti-
bodies was carried out in blocking solution. Sections were then
counterstained with DAPI and mounted in Vectashield. Stained
samples were analyzed with a Leica TCS AOBS confocal microscope
using the following objectives: 63× (HCX PL APO lbd.BL NA = 1.4,
oil), 40× (HCX PL APO NA = 1.25, oil), or 20× (HC PL FLUOTAR
NA = 0.5, dry). Leica Confocal Software was used for the acquisition
of images. The figures were assembled using Adobe Photoshop and
Adobe Illustrator. The adjustments used in the preparation of the fig-
ures were for brightness, contrast, and background noise (blur filter).
For lesion quantifications, brains were fixed in 3% PAF over-
night at 4°C and then embedded in 4% low-melting-point agarose.
Serial sagittal sections (150 lm) of the cerebellum were obtained
using a vibratome (1000 Plus, The Vibratome Company, St. Louis,
MO, US). Each section was stained for Glut1 for vessel detection
and examined under confocal microscopy (10× and 20× objectives).
Analysis of the number/size of the CCM cavernae was performed
using ImageJ software. Three different groups of caverns were
defined according to their size (area in lm2) (Boulday et al, 2011).
For immunohistochemistry on human samples, 3-lm paraffin
sections were stained with hematoxylin and eosin (H&E) to assess
the histological features. Immunohistochemical analysis for
CLAUDIN5 and KLF4 was performed on serial sections. Paraffin
was removed with xylene, and the sections were rehydrated in
graded alcohol. Antigen retrieval was carried out using preheated
sodium citrate solution for 50 min. Tissue sections were blocked
with FBS in PBS for 60 min and incubated overnight with primary
antibodies. HRP-Polymer Kit (Biocare Medical, Pike Lane Concord,
CA, USA) was used for the detection of antigens followed by a
diaminobenzidine chromogen reaction (Peroxidase substrate kit,
DAB, SK-4100; Vector Lab). All sections were counterstained with
Mayer’s hematoxylin. Images were acquired using an upright
microscope (Olimpus BX51) using a 20× objective (UPlanFL N 20×
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NA = 0.5). NIS Elements software was used for image analysis.
BMP6 and PECAM1 immunohistochemistry on murine brain
samples were performed as described above for CLAUDIN5 and
KLF4. Antigen retrival was carried out using sodium citrate for
BMP6 and EDTA for PECAM1.
Retinal immunohistochemistry
Retina immunostaining was carried out with littermates processed
simultaneously under the same conditions. The retinae were
dissected from eyes fixed in 2% PFA for 2 h at 4C. After blocking/
permeabilization in 1% BSA, 5% donkey serum and 0.5% Triton
X-100 in PBS overnight, the retinas were washed in Pblec Buffer
(1% Triton X-100, 1 mM CaCl2, 1 mM MgCl2, and 0.1 mM MnCl2 in
PBS, pH 6.8) and incubated overnight at 4° C in Pblec buffer
containing biotinylated isolectin B4 (IB4) and the primary antibod-
ies. Then, the retinae were incubated with fluorophore-conjugated
antibodies and with Alexa Fluor 488/555/647 streptavidin (Life
Technologies) and mounted with ProLong Gold (Life Technologies).
Confocal analysis was performed using a Leica TCS AOBS or Leica
TCS SP5 confocal microscope using the following objectives: 40×
(HCX PL APO NA = 1.25, oil) or 10× (HC PL FLUOTAR NA = 0.3,
dry). Leica Confocal Software was used for the acquisition. The fig-
ures were prepared as described in “brain tissue histology and
immunofluorescence” section.
The vessel front density and vascular progression in the retinae
were performed as previously described (Corada et al, 2013). All
image analyses were carried out using the ImageJ software.
Statistics
Data are expressed as mean  SD. Student’s two-tailed non-paired
t-tests were used to determine the statistical significance for the
in vitro, ex vivo, and in vivo analyses. The significance level was set
at P < 0.05. For survival experiment, Kaplan–Meier curves were
analyzed with the Mantel–Cox test.
Study approval
All experimental animal procedures and the mouse handling
described in this study were in full accordance with the guidelines
established in the Principles of Laboratory Animal Care (directive
86/609/EEC) and approved by the Italian Ministry of Health (project
19/12).
Human brain specimens from familial CCM1 patients were
obtained from Angioma Alliance BioBank upon we got the written
permission of the Angioma Alliance BioBank Scientific Advisory
Board. Informed consent was obtained for all samples linked with
clinical data. All tissue samples were collected and used for stan-
dardized operative procedures approved by the IFOM Ethics
Committee for Biomedical research with the register number 2/14.
Expanded View for this article is available online.
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The paper explained
Problem
Cerebral cavernous malformation (CCM) is a genetic disease charac-
terized by vascular malformations of brain microvessels that result in
neurological signs such as headache, seizures, paralyses, and hemor-
rhagic stroke. The only therapy available is surgery that is, however,
often hazardous depending on the location of the vascular malforma-
tion. CCM is caused by the loss-of-function mutations of any of three
independent genes, known as CCM1, CCM2, and CCM3. We have
recently reported that the TGFb/BMP signaling pathway induces an
endothelial-to-mesenchymal transition (EndMT) in Ccm-deficient ECs
that, in turn, contributes to the development and progression of
cavernomas. However, the molecular basis of the activation of such
signaling route has not yet been clarified.
Results
Here, we identify KLF4 as a master regulator of EndMT during CCM
development and progression. Loss of Ccm1 leads to MEKK3-MEK5-
dependent ERK5 phosphorylation that, in turn, induces a strong
upregulation of Klf4 expression in brain endothelial cells. The resulting
increased KLF4 transcriptional activity is responsible for the EndMT
switch observed in CCM1-null ECs, since it is able to drive the expres-
sion of both molecules responsible for TGFb/BMP signaling activation
and a number of EndMT markers involved in CCM pathogenesis.
Importantly, in vivo Klf4 genetic inactivation blocks the development
and progression of cavernomas and almost completely prevents asso-
ciated mortality.
Impact
Our dissection of the molecular mechanisms underlying cavernoma
pathogenesis unveils KLF4 upregulation as the key initial event in
CCM. In fact, Klf4 gene ablation almost abolishes the appearance of
lesions and mortality in endothelial-specific CCM1-null mice. We thus
suggest KLF4 to be an important novel therapeutic target for the
pharmacological treatment of CCM, which is currently only treatable
with surgical intervention.
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